Effect of calcitonin gene-related peptide (-receptor) antibodies in chronic cluster headache: Results from a retrospective case series support individual treatment attempts.
CGRP
Chronic cluster headache
erenumab
galcanezumab
headache diary
preventive treatment
Journal
Cephalalgia : an international journal of headache
ISSN: 1468-2982
Titre abrégé: Cephalalgia
Pays: England
ID NLM: 8200710
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
pubmed:
19
8
2020
medline:
16
12
2021
entrez:
19
8
2020
Statut:
ppublish
Résumé
To assess the efficacy of monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor in chronic cluster headache (CCH) treatment under real world conditions. Calcitonin gene-related peptide has an important pathophysiological role in cluster headache. Although the randomised controlled trial with the calcitonin gene-related peptide antibody galcanezumab was negative, chronic cluster headache patients with insufficient response to other preventive treatments have been receiving individual off-label treatment attempts with calcitonin gene-related peptide-(receptor) antibodies. Data from 22 chronic cluster headache patients who received at least one dose of a calcitonin gene-related peptide(-receptor) antibody and recorded attack frequency in a headache diary were retrospectively collected at eight headache centres. The number of previous preventive therapies was 6.5 ± 2.4 (mean ± standard deviation, range: 2-11). The average number of attacks per week was 23.3 ± 16.4 at baseline and significantly decreased by -9.2 ± 9.7 in the first month of treatment with a calcitonin gene-related peptide(-receptor) antibody ( Under real-world conditions, individual treatment with calcitonin gene-related peptide(-receptor) antibodies was effective in 55% of our chronic cluster headache patients. This finding supports individual off-label treatment attempts with calcitonin gene-related peptide-(receptor) antibodies in chronic cluster headache patients insufficiently responding to other therapies.
Sections du résumé
OBJECTIVE
To assess the efficacy of monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor in chronic cluster headache (CCH) treatment under real world conditions.
BACKGROUND
Calcitonin gene-related peptide has an important pathophysiological role in cluster headache. Although the randomised controlled trial with the calcitonin gene-related peptide antibody galcanezumab was negative, chronic cluster headache patients with insufficient response to other preventive treatments have been receiving individual off-label treatment attempts with calcitonin gene-related peptide-(receptor) antibodies.
METHODS
Data from 22 chronic cluster headache patients who received at least one dose of a calcitonin gene-related peptide(-receptor) antibody and recorded attack frequency in a headache diary were retrospectively collected at eight headache centres.
RESULTS
The number of previous preventive therapies was 6.5 ± 2.4 (mean ± standard deviation, range: 2-11). The average number of attacks per week was 23.3 ± 16.4 at baseline and significantly decreased by -9.2 ± 9.7 in the first month of treatment with a calcitonin gene-related peptide(-receptor) antibody (
CONCLUSION
Under real-world conditions, individual treatment with calcitonin gene-related peptide(-receptor) antibodies was effective in 55% of our chronic cluster headache patients. This finding supports individual off-label treatment attempts with calcitonin gene-related peptide-(receptor) antibodies in chronic cluster headache patients insufficiently responding to other therapies.
Identifiants
pubmed: 32806953
doi: 10.1177/0333102420949866
pmc: PMC7691634
doi:
Substances chimiques
Receptors, Calcitonin Gene-Related Peptide
0
Calcitonin Gene-Related Peptide
JHB2QIZ69Z
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1574-1584Références
Brain Sci. 2020 Jan 06;10(1):
pubmed: 31935868
Brain. 1994 Jun;117 ( Pt 3):427-34
pubmed: 7518321
Cephalalgia. 2019 Apr;39(5):575-584
pubmed: 30854880
Eur J Neurol. 2020 Apr;27(4):609-618
pubmed: 31692188
J Neurol Neurosurg Psychiatry. 2007 Dec;78(12):1354-8
pubmed: 17442761
Cephalalgia. 2008 Jun;28(6):614-8
pubmed: 18422717
J Headache Pain. 2018 Jul 13;19(1):53
pubmed: 30006780
Lancet. 2019 Nov 9;394(10210):1765-1774
pubmed: 31668411
CNS Drugs. 2020 Feb;34(2):171-184
pubmed: 31997136
JAMA Neurol. 2018 Oct 1;75(10):1187-1197
pubmed: 29987329
Headache. 2020 Feb;60(2):360-369
pubmed: 31762031
Cephalalgia. 2018 Jan;38(1):1-211
pubmed: 29368949
Headache. 2020 Feb;60(2):348-359
pubmed: 31710104
J Headache Pain. 2014 Nov 27;15:79
pubmed: 25430992
N Engl J Med. 2019 Jul 11;381(2):132-141
pubmed: 31291515
J Headache Pain. 2018 Oct 1;19(1):92
pubmed: 30276500
J Headache Pain. 2019 Jun 3;20(1):66
pubmed: 31159727
Eur J Neurol. 2006 Oct;13(10):1066-77
pubmed: 16987158
N Engl J Med. 2017 Nov 30;377(22):2123-2132
pubmed: 29171821
Lancet. 2018 Nov 24;392(10161):2280-2287
pubmed: 30360965
Cephalalgia. 1995 Dec;15(6):452-62
pubmed: 8706107
Headache. 2020 Jun;60(6):1187-1195
pubmed: 32359106
Lancet Neurol. 2018 Jan;17(1):75-83
pubmed: 29174963
Lancet Neurol. 2015 Nov;14(11):1081-90
pubmed: 26432182
Front Neurol. 2019 Nov 22;10:1220
pubmed: 31824403
J Neurol Sci. 2012 Jun 15;317(1-2):17-28
pubmed: 22482825
Neurology. 2017 Mar 14;88(11):1069-1076
pubmed: 28202701
Cephalalgia. 2017 Apr;37(5):423-434
pubmed: 27165493
Brain. 1997 Feb;120 ( Pt 2):283-8
pubmed: 9117375
Headache. 2020 Apr;60(4):809-818
pubmed: 32108941
Headache. 2019 Jun;59(6):834-847
pubmed: 30942898
Cephalalgia. 2020 Aug;40(9):935-948
pubmed: 32050782